References
Tranexamic acid and international ambulance services
Abstract
Introduction:
Severe haemorrhage may lead to pathologic release of fibrinolytic enzymes, which break down blood clots. Tranexamic acid (TXA) is a drug that inhibits the fibrinolysis of blood clots.
Aim:
The purpose of this review is to explore current literature regarding prehospital TXA administration for patients suffering severe haemorrhage following trauma, and to discuss whether this drug should be more widely used across modern international ambulance services.
Methods:
Literature searches of EBSCO Host, ProQuest and PubMed databases were conducted in August, 2019.
Results:
TXA administration within 3 hours following injury is associated with improved outcomes for severe haemorrhage patients. However, there are reservations that the success of TXA in developing countries and military settings may not be directly transferrable to the modern civilian healthcare systems.
Discussion:
The benefits of prehospital TXA administration appear compelling. Further studies will help guide wider international implementation of this drug in paramedic practice.
Haemorrhagic shock is a leading cause of death internationally, whether from serious trauma (Grassin-Delyle et al, 2018; Neeki et al, 2018) or other conditions such as postpartum haemorrhage (Shakur et al, 2010; Cannon, 2018). Severe haemorrhage can compromise the body's ability to form and maintain clots. This is because haemorrhage, hypoperfusion and haemorrhagic shock may result in dysregulation of coagulation systems, through pathologic release of fibrinolytic enzymes. These fibrinolytic enzymes have the effect of prematurely breaking down clots within the haemorrhaging patient, thereby compromising haemodynamic stability through excessive thrombolysis (Huebner et al, 2017; Grassin-Delyle et al, 2018; Neeki et al, 2018).
Tranexamic acid (TXA) inhibits the premature breakdown of blood clots, which may occur following severe haemorrhage. TXA is a synthetic derivative of lysine that inhibits the fibrinolysis of blood clots (Roberts, 2015; Jawa et al, 2016; MIMS, 2019). TXA appears to be a promising drug that—if administered early, such as during the prehospital phase of care—may reduce mortality from severe haemorrhage (Stansfield et al, 2020). In the United Kingdom (UK), TXA was first introduced to the South Western Ambulance Service Trust in December, 2011 (Paudyal et al, 2017) and has since become widely used by paramedics across the UK when treating patients with severe internal or external haemorrhage, postpartum haemorrhage and head injury (Association of Ambulance Chief Executives, 2019). However, other studies suggest that further research is required to demonstrate the efficacy of prehospital TXA administration (Napolitano, 2017), and it is perhaps for this reason that TXA is not yet widely used across all international ambulance services. For example, TXA administration across Australian ambulance services is largely restricted to the PATCH (2019) research study, while paramedic use of this drug in New Zealand has only recently commenced (St John New Zealand, 2019).
Subscribe to get full access to International Paramedic Practice
Thank you for visiting International Paramedic Practice and reading our archive of expert clinical content. If you would like to read more from the only journal dedicated to those working in emergency care, you can start your subscription today for just £48.
What's included
-
CPD Focus
-
Develop your career
-
Stay informed